A Multicenter, Randomized, Double-blind, Parallel, Excipient-controlled Phase II Clinical Study Evaluating the Efficacy and Safety of SHR0302Base in Subjects With Nonsegmental Vitiligo
Status: Recruiting
Location: See location...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY
The purpose of this study is to evaluate the efficacy and safety of SHR0302Base in participants with nonsegmental vitiligo.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:
• Clinically diagnosis of non-segmental vitiligo.
• The disease has been stable for more than 3 months (90 days) (stable disease is defined as no expansion of the original lesion and no new lesions).
• Subjects and their partners do not plan to have children, do not donate sperm/eggs, and voluntarily use highly effective contraception during the study period until 6 months (female subjects) or 3 months (male subjects) after dosing. Female subjects must have a negative serum pregnancy test and be non-lactating.
Locations
Other Locations
China
Dermatology Hospital affiliated to Shandong First Medical University
RECRUITING
Jinan
Contact Information
Primary
Hui Wang, M.M
hui.wang.hw119@hengrui.com
+86-0518-82342973
Time Frame
Start Date: 2025-02-11
Estimated Completion Date: 2026-04
Participants
Target number of participants: 152
Treatments
Experimental: Treatment group 1
Experimental: Treatment group 2
Experimental: Treatment group 3
Placebo_comparator: Treatment group 4
Related Therapeutic Areas
Sponsors
Leads: Jiangsu HengRui Medicine Co., Ltd.